Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3) - an AIO phase II study (EVINEC)

被引：0

作者：

Pavel, Marianne ^{[1
]}

Kloeppel, Guenter ^{[2
]}

von Weikersthal, Ludwig Fischer ^{[3
]}

Hoersch, Dieter ^{[4
]}

Mayer, Karin ^{[5
]}

Schrader, Joerg ^{[6
]}

Augustin, Marinela ^{[7
]}

Venerito, Marino ^{[8
]}

Krause, Katrin ^{[9
]}

Apostolidis, Leonidas ^{[10
]}

机构：

[1] Univ Klin Erlangen, Endocrinol Dept, Gastroenterol & Hepatol, Erlangen, Germany

[2] Tech Univ Munich, Inst Pathol, Munich, Germany

[3] Klinikum St Marien Amberg, Onkol Zentrum, Amberg, Germany

[4] Zentralklin Bad Berka, Dept Internal Med Gastroenterol & Endocrinol, Bad Berka, Germany

[5] Univ Klinikum Bonn, Dept Haematol & Oncol, Bonn, Germany

[6] Univ Klinikum Hamburg Eppendorf, Ctr Internal Med, Hamburg, Germany

[7] Klinikum Nurnberg, Ctr Oncol Haematol, Clin Internal Med, Nurnberg, Germany

[8] Univ Klin Magdeburg, Dept Gastrointestinal Oncol, Magdeburg, Germany

[9] AIO Studien gGmbH, Project Management Sponsor, Berlin, Germany

[10] Natl Ctr Tumor Dis NCT Heidelberg, Dept Med Oncol, Heidelberg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1020

引用

页码：236 / 236

页数：1

共 50 条

[1] Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC)
Pavel, M. E.
von Weikersthal, L. Fischer
Kloeppel, G.
Krause, K.
Apostolidis, L.
ANNALS OF ONCOLOGY, 2023, 34 : S702 - S702
[2] Treatment outcomes of patients with G3 neuroendocrine neoplasms
Jann, Henning
Kayser, Antonin
Wiedenmann, Bertram
Tacke, Frank
Roderburg, Christoph
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[3] Treatment outcomes of patients with G3 neuroendocrine neoplasms
Jann, H.
Wiedenmann, B.
Tacke, F.
Roderburg, C.
JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 137 - 137
[4] Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms
Schenk, J.
Kayser, A.
Wiedenmann, B.
Tacke, F.
Roderburg, C.
Jann, H.
NEUROENDOCRINOLOGY, 2020, 110 : 203 - 203
[5] Everolimus in Pancreatic Neuroendocrine Carcinomas G3
Panzuto, F.
Rinzivillo, M.
Spada, F.
Antonuzzo, L.
Ibrahim, T.
Campana, D.
Fazio, N.
Delle Fave, G.
NEUROENDOCRINOLOGY, 2016, 103 : 83 - 83
[6] Everolimus in Pancreatic Neuroendocrine Carcinomas G3
Panzuto, Francesco
Rinzivillo, Maria
Spada, Francesca
Antonuzzo, Lorenzo
Ibrahim, Toni
Campana, Davide
Fazio, Nicola
Delle Fave, Gianfranco
PANCREAS, 2017, 46 (03) : 302 - 305
[7] Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Velayoudom-Cephise, Fritz-Line
Duvillard, Pierre
Foucan, Lydia
Hadoux, Julien
Chougnet, Cecile N.
Leboulleux, Sophie
Malka, David
Guigay, Joel
Goere, Diane
Debaere, Thierry
Caramella, Caroline
Schlumberger, Martin
Planchard, David
Elias, Dominique
Ducreux, Michel
Scoazec, Jean-Yves
Baudin, Eric
ENDOCRINE-RELATED CANCER, 2013, 20 (05) : 649 - 657
[8] Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
Heetfeld, M.
Chougnet, C. N.
Olsen, I. H.
Rinke, A.
Borbath, I.
Crespo, G.
Barriuso, J.
Pavel, M.
O'Toole, D.
Walter, T.
ENDOCRINE-RELATED CANCER, 2015, 22 (04) : 657 - 664
[9] Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)
Morken, S.
Langer, S. W.
Sundlov, A.
Detlefsen, S.
Krogh, M.
Tabaksblat, E.
Hjortland, G. O.
Svensson, J. B.
Assmus, J.
Couvelard, A.
Perren, A.
Sorbye, H.
JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 181 - 181
[10] Genetic profile of pancreatic neuroendocrine neoplasms G3
Konukiewitz, B.
Jesinghaus, M.
Schlitter, A. M.
Kasajima, A.
Steiger, K.
Zamboni, G.
Weichert, W.
Kloeppel, G.
Pfarr, N.
VIRCHOWS ARCHIV, 2017, 471 : S7 - S7

← 1 2 3 4 5 →